. . "Sneller, Vesna" . "Bellmunt, Joaquim" . "219160" . "8"^^ . . "10.1111/j.1464-410X.2010.09707.x" . . "tyrosine kinase inhibitors; sequencing; overall survival; metastatic RCC; bevacizumab"@en . "2" . "Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial"@en . . "[ACDFEF01413B]" . . . "RIV/00179906:_____/11:10110344!RIV12-MZ0-00179906" . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "Bracarda, Sergio" . "Bajetta, Emilio" . . "N, S" . . . "6"^^ . "http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2010.09707.x/pdf" . "BJU International" . "RIV/00179906:_____/11:10110344" . "Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial" . "To retrospectively evaluate the effect of subsequent tyrosine kinase inhibitors (TKIs) after first-line bevacizumab + interferon-alfa2a (IFN) or IFN + placebo in the phase III AVOREN (Avastin and Roferon in Renal Cell Carcinoma) trial. Multiple active treatment options are available for patients with mRCC. Current data suggest that it is difficult to use these therapies in combination due to toxicity concerns. The ability to use these active therapies sequentially provides the potential for improved patient outcomes."@en . "000285922200005" . . "N\u00E9grier, Sylvie" . "Escudier, Bernard" . "Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial"@en . "Ravaud, Alain" . . . . "1"^^ . "Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial" . "To retrospectively evaluate the effect of subsequent tyrosine kinase inhibitors (TKIs) after first-line bevacizumab + interferon-alfa2a (IFN) or IFN + placebo in the phase III AVOREN (Avastin and Roferon in Renal Cell Carcinoma) trial. Multiple active treatment options are available for patients with mRCC. Current data suggest that it is difficult to use these therapies in combination due to toxicity concerns. The ability to use these active therapies sequentially provides the potential for improved patient outcomes." . "107" . . . . . "Melichar, Bohuslav" . "1464-4096" .